Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herceptin added to capecitabine + vinorelbine in HER2-positive metastatic breast cancer after trastuzumab + taxane progression
2005-000405-56Phase 4Active
- Sponsor
- GEICAM
- Start
- May 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in breast cancer comparing Herceptin + capecitabine + vinorelbine with Capecitabine + vinorelbine (2 arms). Primary endpoint: Clinical benefit rate. Started May 2006; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-000405-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000405-56.